Prostate Cancer Personalized Therapy

CE / CME

Expert Think Tank on Applying the Latest Data to Individualize Treatment in Prostate Cancer

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 16, 2023

Expiration: August 15, 2024

Tanya B. Dorff
Tanya B. Dorff, MD
Rana R. McKay
Rana R. McKay, MD
Alicia Morgans
Alicia Morgans, MD, MPH
Michael Schweizer
Michael Schweizer, MD
David VanderWeele
David VanderWeele, MD, PhD

Activity

Progress
1
Course Completed

References

  1. Lillard JW Jr, Moses KA, Mahal BA, et al. Racial disparities in Black men with prostate cancer: a literature review. Cancer. 2022;128:3787-3795.
  2. Yamoah K, Lee KM, Awasthi S, et al. Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs health care system. JAMA Netw Open. 2022;5:e2144027.
  3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prostate cancer. v.2.2023. nccn.org. Accessed July 30, 2023.
  4. Anantharaman A, Small EJ. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. Expert Rev Anticancer Ther. 2017;17:625-633. 
  5. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352-360.
  6. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338-351.
  7. Armstrong AJ, Szmuleqitz RZ, Patrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974-2986.
  8. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121-131.
  9. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13-24.
  10. Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132-1142.
  11. Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399:1695-1707.
  12. Hussain M, Tombal B, Saad F, et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol. 2023;41:3595-3607.
  13. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080-1087.
  14. Tripathi A, Chen YH, Frazier, D, et al. Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): an analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 5081.
  15. James ND, Ingleby FC, Clarke NW, et al. Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial. JNCI Cancer Spetr. 2022;6:pkac043.
  16. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446-453.
  17. Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650-659. 
  18. Siva S, Bressel M, Murphy DG, et al. Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74:455-462.
  19. Connor MJ, Smith A, Miah S, et al. Targeting oligometastasis with stereotactic ablative radiation therapy or surgery in metastatic hormone-sensitive prostate cancer: a systematic review of prospective clinical trials. Eur Urol Oncol. 2020;3:582-593.
  20. Cahill EM, Pfail JL, Fu MZ, et al. Metastasis-directed therapy for oligometastatic castration-sensitive prostate cancer: an alternative to ADT? Curr Urol Rep. 2023;24:299-306. 
  21. Vanden Berg RNW, Zilli T, Achard V, et al. The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: a review. Prostate Cancer Prostatic Dis. 2023;Epub ahead of print.
  22. Shore ND, Luz M, De Giorgi U, et al. EMBARK: a phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer. Presented at: 2023 American Urological Association Annual Meeting; April 28 - May 1, 2023. Abstract LBA02-09.
  23. Aggarwal R, Heller G, Hillman D, et al. PRESTO: a phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19). Presented at: 2022 European Society for Medical Oncology Congress; September 9-13, 2022. Abstract LBA63.
  24. Aggarwal R, Eggener S, Heller G, et al. Updated progression-free survival from PRESTO: a phase 3 randomized study of androgen annihilation for high-risk biochemically relapsed prostate cancer (AFT-19). Presented at: 2023 American Urological Association Annual Meeting; April 28 - May 1, 2023. Abstract LBA02-11.
  25. Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016;17:727-737.
  26. Hadaschik BA, Eiber M, Weber M, et al. D. Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): an international multicenter retrospective study. Presented at: American Society of Clinical Oncology Annual Meeting 2023; June 2-6, 2023. Abstract 5010.
  27. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103.
  28. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983-992.
  29. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152-160.
  30. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424-433.
  31. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197.
  32. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
  33. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223.
  34. Lutetium-177-PSMA-617 [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc; 2022.
  35. Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797-804.
  36. Hofman MS, Emmett L, Sandhu S, et al. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—overall survival after median follow-up of 3 years (ANZUP 1603). Presented at: 2022 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2022. Abstract 5000.
  37. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1.
  38. Olaparib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2023.
  39. Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023. Epub ahead of print. 
  40. Talazoparib [prescribing information]. New York, NY: Pfizer Labs; 2023.
  41. Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388:719-732.
  42. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091-2102.
  43. Attard G, Borre M, Gurney H, et al. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol. 2018;36:2639-2646.
  44. de Bono JS, Chowdhury S, Feyerabend S, et al. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for ≥24 weeks in Europe. Eur Urol. 2018;74:37-45. 
  45. de Kouchkovsky I, Rao A, Carneiro BA, et al. A phase Ib/II study of the CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2022;28:1531-1539.
  46. Palmbos PL, Daignault-Newton S, Tomlins SA, et al. A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone-sensitive prostate cancer. Clin Cancer Res. 2021;27:3017-3027. 
  47. Gao X, Burris HA, Vuky J, et al. ASCO GU 2022. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium 2022; February 17-19, 2022. Abstract 17.
  48. Fizazi K, Cook N, Barthélémy P, et al. Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES). Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium 2022; February 17-19, 2022. Abstract 18.
  49. Dorff TB, Blanchard S, Martirosyan H, et al. Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC). Presented at: American Society of Clinical Oncology Annual Meeting 2022; June 3-7, 2022. Abstract 5019.
  50. Slovin SF, Dorff TB, Falchook GS, et al. Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC). Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium 2022; February 17-19, 2022. Abstract 98.
  51. Tran B, Horvath L, Dorff T, et al. Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2020 European Society for Medical Oncology Virtual Congress; September 19 - October 18, 2020. Abstract 6090.
  52. Sandhu S, Joshua AM, Emmett L, et al. LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 5005.